

Precisions biologics for advanced spinal fusion



Market context

Biologics drive 60% of spinal fusion outcomes but carry a heavy burden of complications and cost.

rhBMP-2 remains the gold standard and yet uncontrolled release can lead to ectopic bone growth and high revision rates.



The problem

Existing rhBMP-2 delivery systems have suffered from unpredictable dose release, ectopic bone formation and off-label use concerns.

Surgeons want BMP-2 efficacy without the challenges.

The Innovation

Controlled-release technology reshaping BMP-2 perspectives



Encapsulation provides critical dose shielding to prevent early BMP-2 presentation.



LDGraft mimics natural biology, aligning growth factor delivery with the body's regenerative timeline.



Excellent handling as a putty, ready for implantation.



LDGraft's solid-dose form opens the door for new formats.

Traction

1. Successfully completed one of the largest pre-clinical studies with 120 sheep.
2. Backed by leading clinical Key Opinion Leaders.
3. FDA recognition with multiple Breakthrough Device Designations.



Clinical Edge



Largest sheep study in the field and no adverse events.



Human trials underway with active pilot studies in the US and Australia.



Preparing for a full-scale human pivotal study.

The ask

Locate Bio is seeking strategic, licensing and co-development opportunities to advance LDGraft.

Find out more:

<https://www.merciaventures.co.uk/future-of-fusion/locate-bio/>

